Strides Pharma Science Limited

NSEI:STAR 株式レポート

時価総額:₹138.3b

Strides Pharma Science 過去の業績

過去 基準チェック /26

Strides Pharma Scienceの収益は年間平均-29.6%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間13.3% 6.8%割合で 増加しています。 Strides Pharma Scienceの自己資本利益率は7.8%であり、純利益率は4%です。

主要情報

-29.6%

収益成長率

-29.7%

EPS成長率

Pharmaceuticals 業界の成長17.5%
収益成長率6.8%
株主資本利益率7.8%
ネット・マージン4.0%
前回の決算情報30 Sep 2024

最近の業績更新

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Nov 01
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Recent updates

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Nov 01
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Oct 21
Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Aug 14
After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Apr 04
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Feb 29
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Dec 23
Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Sep 26
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Jun 08
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02
Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Jun 25
Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Dec 21
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28
Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Apr 13
Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

Mar 04
Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Feb 15
These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

Jan 26
Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

Jan 11
The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

収支内訳

Strides Pharma Science の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NSEI:STAR 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
30 Sep 2444,1031,7718,6750
30 Jun 2442,086-4757,9580
31 Mar 2440,511-1,2488,0340
31 Dec 2339,535-1,5257,6420
30 Sep 2337,806-2,2807,6070
30 Jun 2336,783-9247,1590
31 Mar 2336,884-2,2127,6860
31 Dec 2235,680-1,8247,3950
30 Sep 2234,976-2,2417,3850
30 Jun 2233,220-3,9096,6920
31 Mar 2230,703-4,6026,7280
31 Dec 2131,127-4,4256,6360
30 Sep 2131,504-2,8306,1200
30 Jun 2132,224-5435,8170
31 Mar 2133,1592,5455,7040
31 Dec 2030,260285,3590
30 Sep 2029,2645895,1920
30 Jun 2028,4801,2664,9060
31 Mar 2027,5204924,5790
31 Dec 1935,8282,8595,8720
30 Sep 1934,2032,1695,5360
30 Jun 1932,2487455,3460
31 Mar 1921,7848403,7070
31 Dec 1828,547-935,3490
30 Sep 1828,0901395,4200
30 Jun 1828,4514154,3630
31 Mar 1828,4515445,3340
31 Dec 1735,8101,0506,9210
30 Sep 1736,5931,1246,9310
30 Jun 1735,3571,7126,0640
31 Mar 1727,5542,3354,8600
31 Dec 1637,2372,8406,9840
30 Sep 1636,5732,4106,7600
30 Jun 1634,1892,1686,0610
31 Mar 1628,6221,3174,0260
31 Dec 1524,9011,1525,5080
30 Sep 1512,9628603,3670
30 Jun 1512,1052443,2060
31 Mar 1511,958161,9940
31 Mar 1410,728-1,8672,3290

質の高い収益: STARは 高品質の収益 を持っています。

利益率の向上: STAR過去に利益を上げました。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: STARの収益は過去 5 年間で年間29.6%減少しました。

成長の加速: STARは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: STAR昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( 20.5% ) と比較することは困難です。


株主資本利益率

高いROE: STARの 自己資本利益率 ( 7.8% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘